These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 33569681

  • 1. A Review of Complement Activation in SLE.
    Weinstein A, Alexander RV, Zack DJ.
    Curr Rheumatol Rep; 2021 Feb 10; 23(3):16. PubMed ID: 33569681
    [Abstract] [Full Text] [Related]

  • 2. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
    Lonati PA, Scavone M, Gerosa M, Borghi MO, Pregnolato F, Curreli D, Podda G, Femia EA, Barcellini W, Cattaneo M, Tedesco F, Meroni PL.
    Front Immunol; 2019 Feb 10; 10():773. PubMed ID: 31031764
    [Abstract] [Full Text] [Related]

  • 3. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
    Hui-Yuen JS, Gartshteyn Y, Ma M, O'Malley T, Conklin J, Eichenfield AH, Imundo LF, Dervieux T, Askanase AD.
    Lupus; 2018 Dec 10; 27(14):2262-2268. PubMed ID: 30376789
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA, Ramsey-Goldman R.
    Arthritis Rheum; 1996 Jul 10; 39(7):1178-88. PubMed ID: 8670328
    [Abstract] [Full Text] [Related]

  • 5. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
    Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A.
    Arthritis Rheum; 2012 Dec 10; 64(12):4040-7. PubMed ID: 22932861
    [Abstract] [Full Text] [Related]

  • 6. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
    Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM, Manzi S.
    Arthritis Rheum; 2010 Mar 10; 62(3):837-44. PubMed ID: 20187154
    [Abstract] [Full Text] [Related]

  • 7. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
    Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM.
    Clin Transl Sci; 2009 Aug 10; 2(4):300-8. PubMed ID: 20161444
    [Abstract] [Full Text] [Related]

  • 8. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL, Roubey RAS, Kitzmiller KJ, Zhou D, Nagaraja HN, Mulvihill E, Barbar-Smiley F, Ardoin SP, Wu YL, Yu CY.
    Front Immunol; 2019 Aug 10; 10():885. PubMed ID: 31134052
    [Abstract] [Full Text] [Related]

  • 9. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
    Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A.
    Arthritis Rheumatol; 2020 Jan 10; 72(1):78-88. PubMed ID: 31469249
    [Abstract] [Full Text] [Related]

  • 10. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.
    Negoro N, Okamura M, Takeda T, Koda S, Amatsu K, Inoue T, Curd JG, Kanayama Y.
    Arthritis Rheum; 1989 Oct 10; 32(10):1233-42. PubMed ID: 2803326
    [Abstract] [Full Text] [Related]

  • 11. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
    Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, Bruchas RR, Staten NR, Olson PK, Stiening CM, Atkinson JP.
    Arthritis Rheumatol; 2019 Mar 10; 71(3):420-430. PubMed ID: 30294950
    [Abstract] [Full Text] [Related]

  • 12. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
    Dervieux T, Conklin J, Ligayon JA, Wolover L, O'Malley T, Alexander RV, Weinstein A, Ibarra CA.
    J Immunol Methods; 2017 Jul 10; 446():54-59. PubMed ID: 28389175
    [Abstract] [Full Text] [Related]

  • 13. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.
    Mejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, Nuñez-Alvarez CA, Morales-Buenrostro LE.
    Clin Rheumatol; 2021 Jun 10; 40(6):2233-2242. PubMed ID: 33170371
    [Abstract] [Full Text] [Related]

  • 14. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.
    Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T.
    Lupus Sci Med; 2014 Jun 10; 1(1):e000056. PubMed ID: 25396070
    [Abstract] [Full Text] [Related]

  • 15. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
    Gartshteyn Y, Mor A, Shimbo D, Khalili L, Kapoor T, Geraldino-Pardilla L, Alexander RV, Conklin J, Dervieux T, Askanase AD.
    Clin Immunol; 2021 Jul 10; 228():108755. PubMed ID: 33984497
    [Abstract] [Full Text] [Related]

  • 16. Cell-bound complement activation products associate with lupus severity in SLE.
    Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T.
    Lupus Sci Med; 2020 Apr 10; 7(1):. PubMed ID: 32371480
    [Abstract] [Full Text] [Related]

  • 17. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
    Svenungsson E, Gustafsson JT, Grosso G, Rossides M, Gunnarsson I, Jensen-Urstad K, Larsson A, Ekdahl KN, Nilsson B, Bengtsson AA, Lood C.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3264-3274. PubMed ID: 32259250
    [Abstract] [Full Text] [Related]

  • 18. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
    Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB.
    Arthritis Rheum; 1992 Jan 01; 35(1):55-61. PubMed ID: 1731815
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
    Li J, An L, Zhang Z.
    Clin Exp Rheumatol; 2014 Jan 01; 32(1):48-53. PubMed ID: 23981509
    [Abstract] [Full Text] [Related]

  • 20. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
    Buyon J, Furie R, Putterman C, Ramsey-Goldman R, Kalunian K, Barken D, Conklin J, Dervieux T.
    Lupus Sci Med; 2016 Jan 01; 3(1):e000165. PubMed ID: 27752336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.